Recent Finacing
Recent Raise
Bexson Biomedical develops a ketamine-based combination platform with BB106, a subcutaneous formulation for postoperative pain, wearable programmable subcutaneous delivery device, and NMDA-targeting compounds; pursuing preclinical and GMP scale-up.
